Geode Capital Management, LLC Neu Base Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.18 - $0.3 $107 - $179	-598 Reduced 0.25%	233,973 $44,000
Q2 2022 Aug 12, 2022	SELL	$0.82 - $1.93 $7,718 - $18,167	-9,413 Reduced 3.86%	234,571 $246,000
Q4 2021 Feb 11, 2022	BUY	$2.6 - $4.18 $10,829 - $17,409	4,165 Added 1.74%	243,984 $685,000
Q3 2021 Nov 12, 2021	BUY	$3.27 - $4.76 $19,499 - $28,383	5,963 Added 2.55%	239,819 $865,000
Q2 2021 Aug 13, 2021	SELL	$4.63 - $7.34 $378,127 - $599,450	-81,669 Reduced 25.88%	233,856 $1.12 Million

Q1 2021 May 12, 2021	BUY	$6.92 - $12.36 $426,237 - $761,314	61,595 Added 24.26%	315,525 $2.33 Million
Q4 2020 Feb 12, 2021	BUY	$6.92 - $9.25 $102,505 - $137,020	14,813 Added 6.19%	253,930 $1.77 Million
Q3 2020 Nov 13, 2020	BUY	$7.25 - $9.71 $628,074 - $841,187	86,631 Added 56.81%	239,117 $1.81 Million
Q2 2020 Aug 13, 2020	BUY	$6.69 - $11.51 $911,713 - $1.57 Million	136,280 Added 840.92%	152,486 $1.34 Million
Q4 2019 Feb 13, 2020	BUY	$4.5 - $8.1 $1,107 - $1,992	246 Added 1.54%	16,206 $116,000
Q3 2019 Nov 12, 2019	BUY	$3.15 - $6.59 $50,274 - $105,176	15,960 New	15,960 $79,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.